Zobrazeno 1 - 10
of 2 630
pro vyhledávání: ''
Autor:
David H. Johnson, Roy S. Herbst, Corey J. Langer, Louis Fehrenbacher, William Novotny, Eric Holmgren, Jacques Gaudreault, John Nemunaitis, David M. Jablons, Fairooz F. Kabbinavar, Russell F. DeVore, Lisa A. Damico
Publikováno v:
Journal of Clinical Oncology. 41:2305-2312
Purpose To investigate the efficacy and safety of bevacizumab plus carboplatin and paclitaxel in patients with advanced or recurrent non-small-cell lung cancer. Patients and Methods In a phase II trial, 99 patients were randomly assigned to bevacizum
Autor:
Wierda, W. G., Allan, J. N., Siddiqi, T., Kipps, T. J., Opat, S., Tedeschi, Alessandra, Badoux, X. C., Kuss, B. J., Jackson, S., Moreno, Carol, Jacobs, R. M. D., Pagel, J. M., Flinn, I., Pak, Y., Zhou, Cathy, Szafer-Glusman, E., Ninomoto, J., Dean, James P, James, D. F., Ghia, Paolo, Tam, C. S., Universitat Autònoma de Barcelona
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 34
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
JOURNAL OF CLINICAL ONCOLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
PURPOSE CAPTIVATE ( NCT02910583 ), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leuk
Publikováno v:
EJC Supplements, Vol 16, Iss, Pp 14-23 (2021)
Copyright © 2021 The Author(s). Aim: To evaluate the cost-effectiveness of [177Lu]Lu-DOTA-TATE versus relevant comparators for the treatment of neuroendocrine tumours located in the gastrointestinal tract (GI-NETs) and the pancreas (P-NETs). Materia
Autor:
Qiong Lyu, Jian Zhang, Peng Luo, Ting Wei, Weimin Ding, Linlang Guo, Weiliang Zhu, Qiongyao Wang, Manming Cao
Publikováno v:
Cancer Medicine, Vol 10, Iss 21, Pp 7863-7876 (2021)
Cancer Medicine
Cancer Medicine
Background The majority of patients with small‐cell lung cancer (SCLC) show a good response in the early stages of treatment, but more than 90% of patients will develop drug resistance. Therefore, biomarkers are urgently needed to identify patients
Autor:
Peng Gao, Guanghui Ren
Publikováno v:
Aging (Albany NY)
Non-small cell lung cancer (NSCLC) is the most common type in lung cancer in the world, and it severely threatens the life of patients. Resveratrol has been reported to inhibit cancer. However, mechanisms of resveratrol inhibiting NSCLC were unclear.
Autor:
Ashley Hinson, Rachael R. Schulte, Van Huynh, Michael J. Burke, Jennifer L. McNeer, Etan Orgel, Erin H. Breese, Joanna Pierro, Benjamin A. Mixon, Seth J. Rotz
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 21, Pp 7551-7560 (2021)
Cancer Medicine, Vol 10, Iss 21, Pp 7551-7560 (2021)
Background Pegaspargase (PEG‐ASP) is an integral component of therapy for acute lymphoblastic leukemia (ALL) but is associated with hepatotoxicity that may delay or limit future therapy. Obese and adolescent and young adult (AYA) patients are at hi
Publikováno v:
Prostate Cancer and Prostatic Diseases. 26:53-58
During the past two decades, new antitumor drugs (Abiraterone, Enzalutamide, Radium-223, Cabazitaxel, and Docetaxel) have been introduced for treatment of prostate cancer with distant metastases (mPCa). Each drug have demonstrated a survival gain in
Autor:
Vladimir S. Prassolov, Carol Stocking, Dmitry Konovalov, T D Lebedev, Pavel Spirin, Maria Suntsova, Anton Buzdin, Alexander Roumiantsev, Elmira Vagapova, Maxim Sorokin, Olga Astashkova, Petr M. Rubtsov, Alesya Mikheeva, Uliana Vladimirova
Publikováno v:
Oncogene
Neuroblastoma (NB) has a low frequency of recurrent mutations compared to other cancers, which hinders the development of targeted therapies and novel risk stratification strategies. Multikinase inhibitors have shown potential in treating high-risk N
Autor:
Reenika Aggarwal, Frances A. Shepherd, Penelope A. Bradbury, Adrian G. Sacher, Karmugi Balaratnam, Elliot Charles Smith, M. Catherine Brown, RuiQi Chen, Lawson Eng, Rouhi Fazelzad, Natasha B. Leighl, Katrina Hueniken, Shirley Xue Jiang, Jessica Weiss, Wei Xu, Sze Wah Samuel Chan, Geoffrey Liu
Publikováno v:
Clinical Lung Cancer. 22:390-407
Background Systemic inflammatory response (SIR) may influence prognosis in epidermal growth factor receptor (EGFR)-mutated (m) non–small-cell lung cancer (NSCLC). Pretreatment SIR markers (neutrophil-to-lymphocyte ratio [NLR], platelet-to-lymphocyt
Autor:
Chang-Ming Huang, Wen-Wu Qiu, Chao-Hui Zheng, Su-Yan, Ju-Li Lin, Cheng-Hao Liu, Jia-Bin Wang, Ping Li, Jian-Xian Lin, Guang-Tan Lin, Ze-Ning Huang, Ru-Hong Tu, Long-Long Cao, Jun Lu, Hua-Long Zheng, Qi-Yue Chen, Mi Lin
Publikováno v:
Gastric Cancer. 24:1355-1364
This study evaluated the safety, effectiveness, and feasibility of indocyanine green (ICG) tracing in guiding lymph-node (LN) dissection during laparoscopic D2 radical gastrectomy in patients with advanced gastric cancer (AGC) after neoadjuvant chemo